Overview

Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation

Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are: - To estimate the incidence rate of unexpected adverse events - To characterize the bleeding events and assess risk factors of bleeding - To identify ancillary baseline variables that may also be associated with adverse outcomes
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
Pfizer
Treatments:
Apixaban